ERBB2 and non-small cell lung carcinoma: Trastuzumab-based chemotherapy was not found to be superior to chemotherapy alone whereas selective HER2 TKIs (e.g., poziotinib and pyrotinib) showed better activity in pre-treated NSCLC patients with HER2 mutation [10].